GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acutus Medical Inc (OTCPK:AFIB) » Definitions » Return-on-Tangible-Equity

Acutus Medical (Acutus Medical) Return-on-Tangible-Equity : 0.00% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Acutus Medical Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Acutus Medical's annualized net income for the quarter that ended in Mar. 2024 was $-6.48 Mil. Acutus Medical's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $-2.45 Mil. Therefore, Acutus Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was N/A%.

The historical rank and industry rank for Acutus Medical's Return-on-Tangible-Equity or its related term are showing as below:

AFIB' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -264.56   Med: -119.12   Max: -48.87
Current: -264.56

During the past 6 years, Acutus Medical's highest Return-on-Tangible-Equity was -48.87%. The lowest was -264.56%. And the median was -119.12%.

AFIB's Return-on-Tangible-Equity is ranked worse than
94.47% of 760 companies
in the Medical Devices & Instruments industry
Industry Median: 1.395 vs AFIB: -264.56

Acutus Medical Return-on-Tangible-Equity Historical Data

The historical data trend for Acutus Medical's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acutus Medical Return-on-Tangible-Equity Chart

Acutus Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial - - -119.12 -48.87 -225.10

Acutus Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -98.60 -145.04 -146.00 -918.96 -

Competitive Comparison of Acutus Medical's Return-on-Tangible-Equity

For the Medical Devices subindustry, Acutus Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acutus Medical's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acutus Medical's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Acutus Medical's Return-on-Tangible-Equity falls into.



Acutus Medical Return-on-Tangible-Equity Calculation

Acutus Medical's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-81.663/( (73.436+-0.879 )/ 2 )
=-81.663/36.2785
=-225.10 %

Acutus Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-6.48/( (-0.879+-4.02)/ 2 )
=-6.48/-2.4495
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Acutus Medical  (OTCPK:AFIB) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Acutus Medical Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Acutus Medical's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Acutus Medical (Acutus Medical) Business Description

Traded in Other Exchanges
N/A
Address
2210 Faraday Avenue, Suite 100, Carlsbad, CA, USA, 92008
Acutus Medical Inc is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The company designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. Its product portfolio includes Novel access sheaths, Transseptal crossing tools, Diagnostic and mapping catheters, Ablation catheters, Mapping and imaging consoles and accessories, as well as Supporting algorithms and Software programs. It markets and sells its electrophysiology products worldwide to hospitals and electrophysiologists that treat patients with arrhythmias. It has a business presence in the United States and Europe.
Executives
Takeo Mukai officer: Interim CFO C/O ACUTUS MEDICAL, INC., 2210 FARADAY AVE., SUITE 100, CARLSBAD CA 92008
Jason K Garland director 10000 WEHRLE DRIVE, CLARENCE NY 14031
Kevin Mathews officer: SVP, Global Sales C/O ACUTUS MEDICAL, INC., 2210 FARADAY AVE., SUITE 100, CARLSBAD CA 92008
Charlie Piscitello officer: Chief People Officer 2210 FARADAY AVE #100, CARLSBAD CA 92008
Tom Sohn officer: SVP, Gen. Counsel & Secretary 2210 FARADAY AVE #100, CARLSBAD CA 92008
R Scott Huennekens director C/O VOLCANO CORPORATION, 11455 EL CAMINO REAL, SUITE 460, SAN DIEGO CA 92130
James F. Hinrichs director 3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Niamh Louise Pellegrini director C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Orbimed Rof Ii Llc director, 10 percent owner 601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
David P Bonita director, 10 percent owner C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
James E Flynn director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Orbimed Capital Gp Iv Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
John F Sheridan director C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET, SAN DIEGO CA 92121
David Roman officer: SVP & Chief Financial Officer ACUTUS MEDICAL, INC., 2210 FARADAY AVE, SUITE 100, CARLSBAD CA 92008

Acutus Medical (Acutus Medical) Headlines

From GuruFocus

Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Stock market mentor Stock market mentor 02-01-2023